Erectile Dysfunction - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 121 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Erectile Dysfunction - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Erectile Dysfunction - Pipeline Review, H1 2016', provides an overview of the Erectile Dysfunction pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Erectile Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction
- The report reviews pipeline therapeutics for Erectile Dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Erectile Dysfunction therapeutics and enlists all their major and minor projects
- The report assesses Erectile Dysfunction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Erectile Dysfunction

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Erectile Dysfunction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Erectile Dysfunction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Erectile Dysfunction Overview 10
Therapeutics Development 11
Pipeline Products for Erectile Dysfunction - Overview 11
Pipeline Products for Erectile Dysfunction - Comparative Analysis 12
Erectile Dysfunction - Therapeutics under Development by Companies 13
Erectile Dysfunction - Therapeutics under Investigation by Universities/Institutes 16
Erectile Dysfunction - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Erectile Dysfunction - Products under Development by Companies 21
Erectile Dysfunction - Products under Investigation by Universities/Institutes 23
Erectile Dysfunction - Companies Involved in Therapeutics Development 24
Acorda Therapeutics, Inc. 24
Apricus Biosciences, Inc. 25
Biopharm GmbH 26
Corridor Pharmaceuticals Inc. 27
Futura Medical Plc 28
Hanmi Pharmaceuticals, Co. Ltd. 29
Humanetics Corporation 30
IntelGenx Corp. 31
Mezzion Pharma Co. Ltd. 32
Mitsubishi Tanabe Pharma Corporation 33
Monosol Rx, LLC 34
NAL Pharmaceuticals Ltd. 35
Pacific Therapeutics Ltd. 36
Palatin Technologies, Inc. 37
Pharmicell Co., Ltd. 38
Sihuan Pharmaceutical Holdings Group Ltd. 39
Suda Ltd 40
U.S. Stem Cell, Inc. 41
Yungjin Pharm. Co., Ltd. 42
Erectile Dysfunction - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Combination Products 44
Assessment by Target 45
Assessment by Mechanism of Action 48
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
(PDE-5 Inhibitor + tramadol hydrochloride) - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
AdipoCell - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
alprostadil - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
AP-102 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
avanafil - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
BIO-300 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
BL-214 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
cimaglermin alfa - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
fadanafil - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
HCP-1302 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
HCP-1303 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Immpocellgram - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
MED-2005 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
nitroglycerin - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Recombinant Protein for Degenerative Disc Disease, Bone Fracture, Parkinson's Disease and Erectile Dysfunction - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
sildenafil citrate - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
sildenafil citrate - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
sildenafil citrate - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
SUD-003 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
T-6932 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
tadalafil - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
tadalafil - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
tadalafil - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
TF-0092 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
TPN-171 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
TPN-729 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
TR-399 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
udenafil - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
VLFIA-330 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
YBH-1603 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Erectile Dysfunction - Recent Pipeline Updates 96
Erectile Dysfunction - Dormant Projects 109
Erectile Dysfunction - Discontinued Products 112
Erectile Dysfunction - Product Development Milestones 113
Featured News & Press Releases 113
Jan 29, 2015: VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity 113
Nov 20, 2014: Auxilium Pharmaceuticals Presents STENDRA Data At SMSNA Scientific Meeting 113
Nov 03, 2014: Auxilium Pharmaceuticals To Present STENDRA Data At SMSNA Scientific Meeting 114
Sep 18, 2014: VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity 114
Jul 09, 2014: New Grant Enables Humanetics to Evaluate Potential Treatment for Erectile Dysfunction in Prostate Cancer Patients 115
Apr 11, 2014: VIVUS To Present Clinical Data On Avanafil at European Association of Urology 116
Feb 24, 2014: IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm Tadalafil Product 116
Jan 21, 2014: VIVUS and Auxilium Announce FDA Acceptance of Supplemental Filing Seeking an Update of Prescribing Information for STENDRA (avanafil) 116
Aug 01, 2013: VIVUS Announces Commercial Supply Agreement With Sanofi to Produce Avanafil 117
Jun 26, 2013: Vivus Announces European Approval For Spedra For Treatment Of Erectile Dysfunction 117
Appendix 120
Methodology 120
Coverage 120
Secondary Research 120
Primary Research 120
Expert Panel Validation 120
Contact Us 120
Disclaimer 121

List of Tables
Number of Products under Development for Erectile Dysfunction, H1 2016 11
Number of Products under Development for Erectile Dysfunction - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 14
Number of Products under Development by Companies, H1 2016 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2016 16
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 18
Comparative Analysis by Early Stage Development, H1 2016 19
Comparative Analysis by Unknown Stage Development, H1 2016 20
Products under Development by Companies, H1 2016 21
Products under Development by Companies, H1 2016 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2016 23
Erectile Dysfunction - Pipeline by Acorda Therapeutics, Inc., H1 2016 24
Erectile Dysfunction - Pipeline by Apricus Biosciences, Inc., H1 2016 25
Erectile Dysfunction - Pipeline by Biopharm GmbH, H1 2016 26
Erectile Dysfunction - Pipeline by Corridor Pharmaceuticals Inc., H1 2016 27
Erectile Dysfunction - Pipeline by Futura Medical Plc, H1 2016 28
Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 29
Erectile Dysfunction - Pipeline by Humanetics Corporation, H1 2016 30
Erectile Dysfunction - Pipeline by IntelGenx Corp., H1 2016 31
Erectile Dysfunction - Pipeline by Mezzion Pharma Co. Ltd., H1 2016 32
Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 33
Erectile Dysfunction - Pipeline by Monosol Rx, LLC, H1 2016 34
Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd., H1 2016 35
Erectile Dysfunction - Pipeline by Pacific Therapeutics Ltd., H1 2016 36
Erectile Dysfunction - Pipeline by Palatin Technologies, Inc., H1 2016 37
Erectile Dysfunction - Pipeline by Pharmicell Co., Ltd., H1 2016 38
Erectile Dysfunction - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016 39
Erectile Dysfunction - Pipeline by Suda Ltd, H1 2016 40
Erectile Dysfunction - Pipeline by U.S. Stem Cell, Inc., H1 2016 41
Erectile Dysfunction - Pipeline by Yungjin Pharm. Co., Ltd., H1 2016 42
Assessment by Monotherapy Products, H1 2016 43
Assessment by Combination Products, H1 2016 44
Number of Products by Stage and Target, H1 2016 46
Number of Products by Stage and Mechanism of Action, H1 2016 49
Number of Products by Stage and Route of Administration, H1 2016 51
Number of Products by Stage and Molecule Type, H1 2016 53
Erectile Dysfunction Therapeutics - Recent Pipeline Updates, H1 2016 96
Erectile Dysfunction - Dormant Projects, H1 2016 109
Erectile Dysfunction - Dormant Projects (Contd..1), H1 2016 110
Erectile Dysfunction - Dormant Projects (Contd..2), H1 2016 111
Erectile Dysfunction - Discontinued Products, H1 2016 112